20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
ProKidney Corp. (PROK) operates in the BIOTECHNOLOGY industry and is headquartered in Winston-Salem, United States with about 231 employees. Its market capitalization is roughly $427 million. In the fiscal year ended 2025-12-31, PROK reported $1M in revenue and ($69M) in net income.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.
Interactive charts & full statements → Open the PROK valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1M | $1M | $0M | $0M | $0M | $0M | $0M | — |
| Gross Profit | ($2M) | $1M | $0M | ($3M) | ($3M) | ($2M) | — | — |
| Gross Margin % | -252.6% | 100.0% | 100.0% | — | — | — | — | — |
| Operating Income (EBIT) | ($177M) | ($165M) | ($184M) | ($152M) | ($153M) | ($55M) | ($27M) | ($79M) |
| Operating Margin % | -21664.5% | -18477.8% | -241678.9% | — | — | — | — | — |
| Net Income | ($87M) | ($69M) | ($61M) | ($35M) | ($108M) | ($55M) | ($27M) | ($80M) |
| Net Margin % | -10599.8% | -7725.2% | -80507.9% | — | — | — | — | — |
| EBITDA | ($161M) | ($145M) | ($158M) | ($126M) | ($144M) | ($53M) | ($26M) | ($18M) |
| Earnings Per Share (EPS) | $-0.57 | $-0.52 | $-0.62 | $-0.57 | $-1.76 | $-1.73 | $-0.14 | $-1.01 |
| Shares Outstanding (M) | 187M | 134M | 98M | 62M | 62M | — | 186M | 79M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | ($1M) | ($1M) | $0M | $0M | $0M | $0M | ($1M) |
| Gross Margin % | 100.0% | -535.0% | -544.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Income (EBIT) | ($48M) | ($45M) | ($45M) | ($39M) | ($40M) | ($41M) | ($52M) | ($49M) |
| Operating Margin % | -32248.7% | -19881.9% | -20164.9% | -17759.9% | -17967.9% | -17994.8% | -67856.6% | — |
| Net Income | ($28M) | ($23M) | ($19M) | ($16M) | ($17M) | ($17M) | ($21M) | ($18M) |
| Net Margin % | -18948.0% | -9992.9% | -8547.1% | -7589.4% | -7489.6% | -7275.7% | -27997.4% | — |
| EBITDA | ($45M) | ($41M) | ($41M) | ($34M) | ($35M) | ($36M) | ($45M) | ($42M) |
| Earnings Per Share (EPS) | $-0.15 | $-0.16 | $-0.14 | $-0.12 | $-0.13 | $-0.13 | $-0.17 | $-0.14 |
| Shares Outstanding (M) | 187M | 142M | 140M | 135M | 131M | 129M | 128M | 126M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($141M) | ($120M) | ($126M) | ($90M) | ($77M) | ($50M) | ($25M) | $0M |
| Capital Expenditures (CapEx) | $19M | $15M | $30M | $34M | $2M | $5M | $5M | $0M |
| Free Cash Flow (FCF) | ($160M) | ($135M) | ($156M) | ($124M) | ($79M) | ($55M) | ($31M) | $0M |
| FCF Margin % | -19527.4% | -15152.6% | -205078.9% | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($40M) | ($42M) | ($33M) | ($27M) | ($31M) | ($30M) | ($24M) | ($29M) |
| Capital Expenditures (CapEx) | $4M | $4M | $6M | $5M | $3M | $1M | $26M | $2M |
| Free Cash Flow (FCF) | ($44M) | ($45M) | ($38M) | ($32M) | ($35M) | ($31M) | ($50M) | ($32M) |
| FCF Margin % | -29471.3% | -20119.0% | -17006.7% | -14651.2% | -15623.5% | -13359.6% | -65368.4% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $249M | $336M | $441M | $421M | $518M | $40M | $17M | $20M |
| Cash & Cash Equivalents | $75M | $109M | $99M | $61M | $490M | $21M | $5M | $15M |
| Total Liabilities | $26M | $35M | $39M | $29M | $13M | $13M | $7M | $4M |
| Total Debt (Short + Long-Term) | $1M | $1M | $1M | $1M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | ($884M) | ($1.0B) | ($995M) | ($1.1B) | ($1.1B) | $27M | $10M | $16M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PROK viewer.
About TickerBase · Data methodology & sources · Privacy · Terms